Presented at the Global Pharma R&D Informatics Congress. To find out more, visit: www.global-engage.com In this presentation, Jonny Wray from e-Therapeutics discusses network-driven drug discovery, the application of concept, details of implementation and validation of the approach.

3. •
•
DNA RNA Protein Protein-Protein Pathway Pathway-Pathway Network Networks of Higher Order Trait
Interaction Interaction Networks Networks

5. 5
Disease Network
H um an Protein Interactom e
S ystem -w ide m easurem ents Disease and biolog ical
system knowledge
C ontextual
inform ation
Extraction of sub-networks related to targeted disease processes
Different reconstruction alg orithm s
Data Driven Knowledge Driven

6. 6
Networks are robust to random perturbation… … but susceptible to targeted perturbation
Videos Removed

7. 7

10. •
•
•
•
•

11. Inclusion Criteria Positives
MW (300-550) 12225
H acceptors (1-10) 12368
H donors (1-5) 16434
Rotatable bonds (2-10) 13242
TPSA (50-130) 14485
xLogP (0.5-5) 13798
Unnamed 15721

12. •
•
•
•
Telomerase signalling Oncology 393 4.3% 6
Hedgehog pathway Oncology 1146 5.5% 20
TNFα release Autoimmunity 356 7.3% 12
Influenza replication Antiviral 1048 2.2% 4
Tryptophan catabolism Immune oncology 273 11% 4
Systemic inflammatory response
syndrome
Immunology 292 11% 4
Axonal degeneration CNS 1696 3.4% 9
Reversal of T-cell exhaustion Immune oncology 483 on-going -

13. Perscreen
Compoundsassayed
10
2
10
3
10
4
10
5
10
6
10
7
NDD guided vs other
PDD
0
5
10
15
%hits
13
Telomerase signalling Oncology 393 4.3% 6
Hedgehog pathway Oncology 1146 5.5% 20
TNFα release Autoimmunity 356 7.3% 12
Influenza replication Antiviral 1048 2.2% 4
Tryptophan catabolism Immune oncology 273 11% 4
Systemic inflammatory response
syndrome
Immunology 292 11% 4
Axonal degeneration CNS 1696 3.4% 9
Reversal of T-cell exhaustion Immune oncology 483 on-going -

14. α
14

15. μ

16. •
• α
•
•
•
• ҂
҃
•
• ҂
҃
•
•
•